Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
ImmuPharma PLC is a biotechnology company focused on developing innovative therapeutics for autoimmune diseases, particularly its lead product, Lupuzor, which targets systemic lupus erythematosus. The company operates primarily in the UK and has a unique peptide-based platform that differentiates it from competitors in the biopharmaceutical space.
ImmuPharma's business model relies on the successful development and commercialization of its proprietary drug candidates, particularly Lupuzor. The company aims to leverage partnerships with larger pharmaceutical firms for funding and distribution, which provides a potential revenue stream without incurring significant upfront costs.
Clinical trial results for Lupuzor, particularly Phase III outcomes
Partnership announcements with larger pharmaceutical companies
Regulatory approvals or setbacks from health authorities
Market sentiment regarding autoimmune disease treatments
Regulatory changes impacting drug approval processes
Technological disruption in drug development methodologies
Emergence of alternative therapies for lupus and autoimmune diseases
Increased competition from larger biotech firms with more resources
High cash burn rate due to R&D expenditures
Dependence on external funding for operational sustainability
low - The biotechnology sector is generally less sensitive to economic cycles, as demand for healthcare remains relatively stable regardless of economic conditions.
Moderate - Rising interest rates could increase the cost of capital for funding R&D, potentially impacting the pace of development and partnerships.
minimal - The company has no debt, reducing its exposure to credit market fluctuations.
growth - Investors looking for high-risk, high-reward opportunities in biotech will find ImmuPharma appealing due to its innovative pipeline.
high - The stock has exhibited significant price fluctuations, reflecting the inherent risks in biotech development.